ArticleNature communications2020
Transcriptomic analysis links diverse hypothalamic cell types to fibroblast growth factor 1-induced sustained diabetes remission.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 55 citations in OpenAlex.
- Engineered Brain-Targeted Exosomes Delivering FGF1 for Sustained Glycemic Regulation and Multitarget Neurovascular Protection in Diabetic Stroke.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Generation of human appetite-regulating neurons and tanycytes from pluripotent stem cells.Cell stem cell · 2026Article
- Emerging role of AgRP neurons as integrators of metabolic, sensory and environmental cues in the control of energy homeostasis.Reviews in endocrine & metabolic disorders · 2026Review
- Selective deletion of FGFR1 in AgRP neurons impairs energy homeostasis under high-fat diet in mice.Molecular metabolism · 2026Article
- Reducing methylation of histone 3.3 lysine 4 in the medial ganglionic eminence and hypothalamus recapitulates neurodevelopmental disorder phenotypes.Nature communications · 2026Article
- High fat diet remodels the gene regulatory networks in the preoptic area.Scientific reports · 2026Article
- Sustained diabetes remission induced by FGF1 involves a shift in transcriptionally distinct AgRP neuron subpopulations.Molecular metabolism · 2026Article
- Is Hypothalamic Dysfunction a Cause of Type II Diabetes Mellitus?Neuroendocrinology · 2026Review
- A key role for parabrachial nucleus CGRP neurons in FGF1-Induced anorexia.Molecular metabolism · 2025Article
- AgRP neuron hyperactivity drives hyperglycemia in a mouse model of type 2 diabetes.The Journal of clinical investigation · 2025Article
- FGF-based drug discovery: advances and challenges.Nature reviews. Drug discovery · 2025Review
- Review
- Brain Defense of Glycemia in Health and Diabetes.Diabetes · 2024Review
- A single-cell transcriptomic study of heterogeneity in human embryonic tanycytes.Scientific reports · 2024Article
- Targeting the Epigenetic Marks in Type 2 Diabetes Mellitus: Will Epigenetic Therapy Be a Valuable Adjunct to Pharmacotherapy?Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Hypoxia-inducible factor 1 signaling drives placental aging and can provoke preterm labor.eLife · 2023Article
- Review
- The Significance of Hypothalamic Inflammation and Gliosis for the Pathogenesis of Obesity in Humans.Endocrine reviews · 2023Review
- Understanding the aging hypothalamus, one cell at a time.Trends in neurosciences · 2022Review
- Sustained inhibition of NPY/AgRP neuronal activity by FGF1.JCI insight · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 8 institutions in 4 countries.
Marie A Bentsen *UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.
Dylan M Rausch *Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-6095-4891
Zaman MirzadehBarrow Neurological Institute, Phoenix, AZ, USA.ORCID http://orcid.org/0000-0001-5554-9744
Kenjiro MutaUW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-7913-1203
Jarrad M ScarlettUW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-1019-346X
Jenny M BrownUW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-5072-4491
Vicente Herranz-PérezCavanilles Institute of Biodiversity and Evolutionary Biology, University of Valencia, Valencia, Spain.ORCID http://orcid.org/0000-0002-1969-1214
Arian F BaqueroObesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.ORCID http://orcid.org/0000-0003-2153-4688
Jonatan ThompsonNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-4969-9927
Kimberly M AlongeUW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.
Chelsea L FaberUW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-4812-8164
Karl J KaiyalaDepartment of Oral Health Sciences, School of Dentistry, University of Washington, Seattle, WA, USA.
Camdin BennettObesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
Charles PykePathology & Imaging, Global Discovery and Development Sciences, Novo Nordisk A/S, Maaloev, Denmark.
Cecilia RatnerNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Kristoffer L EgerodNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-2781-1594
Birgitte HolstNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-7432-097X
Thomas H MeekObesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
Burak KutluObesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.ORCID http://orcid.org/0000-0001-6854-327X
Yu ZhangObesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
Thomas SparsoBioinformatics and Data Mining, Global Research Technologies, Novo Nordisk A/S, Maaloev, Denmark.
Kevin L GroveObesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
Gregory J MortonUW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-8106-8386
Birgitte R KornumDepartment of Neuroscience, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-2515-9451
José-Manuel García-VerdugoCavanilles Institute of Biodiversity and Evolutionary Biology, University of Valencia, Valencia, Spain.ORCID http://orcid.org/0000-0001-9872-6499
Anna SecherDiabetes Research, Global Drug Discovery, Novo Nordisk A/S, Maaloev, Denmark.ORCID http://orcid.org/0000-0002-6276-5389
Rasmus JorgensenDiabetes Research, Global Drug Discovery, Novo Nordisk A/S, Maaloev, Denmark.
Michael W SchwartzUW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA. mschwart@uw.edu.ORCID http://orcid.org/0000-0003-1619-0331
Tune H PersNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. tune.pers@sund.ku.dk.ORCID http://orcid.org/0000-0003-0207-4831
University of Copenhagen · DKUniversity of Washington · USNovo Nordisk (United States) · USNovo Nordisk (Denmark) · DKBarrow Neurological Institute · USSeattle Children's Hospital · USUniversitat de València · ESUniversitat Jaume I · ES
Funding
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4MPILOT STUDY--CLINICAL NUTRITION RESEARCHP30DK035816 · NIDDK · UNIVERSITY OF WASHINGTON · PI GREGORY J MORTON · 1986 to 2026
$30.4MEXPERIMENTAL PATHOLOGY OF CARDIOVASCULAR DISEASET32HL007312 · NHLBI · UNIVERSITY OF WASHINGTON · PI MAJESKY, MARK W., SCHWARTZ, STEPHEN MARK · 1985 to 2019
$11.8MDiabetes, Obesity and Metabolism Training ProgramT32DK007247 · NIDDK · UNIVERSITY OF WASHINGTON · PI GREGORY J MORTON, KRISTINA Marie UTZSCHNEIDER · 1986 to 2026
$10.0MNovel Brain Mechanisms Controlling Glucose HomeostasisR01DK083042 · NIDDK · UNIVERSITY OF WASHINGTON · PI SCHWARTZ, MICHAEL W · 2008 to 2025
$7.6MNutrition, Obesity and Atherosclerosis Training ProgramT32HL007028 · NHLBI · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1985 to 2026
$6.4MNeuroendocrine Control of Glucose MetabolismR01DK089056 · NIDDK · UNIVERSITY OF WASHINGTON · PI MORTON, GREGORY J · 2011 to 2024
$5.6MNovel Anti-Diabetic Actions of Hypothalamic FGF19-FGFR1 SignalingR01DK101997 · NIDDK · UNIVERSITY OF WASHINGTON · PI SCHWARTZ, MICHAEL W · 2014 to 2018
$1.9MCentral and Peripheral Mechanisms of FGF1-Mediated Remission of Diabetic HyperglycemiaK08DK114474 · NIDDK · UNIVERSITY OF WASHINGTON · PI SCARLETT, JARRAD M · 2017 to 2021
$813kLeica SP8 WWL Confocal MicroscopeS10OD016240 · OD · UNIVERSITY OF WASHINGTON · PI CATTERALL, WILLIAM A · 2014 to 2014
$581kNHLBI NIH HHS T32 HL007028NHLBI NIH HHS T32 HL007312NIDDK NIH HHS K08 DK114474NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK035816NIDDK NIH HHS R01 DK083042NIDDK NIH HHS R01 DK089056NIDDK NIH HHS R01 DK101997NIDDK NIH HHS T32 DK007247NIH HHS S10 OD016240
Abstract
In rodent models of type 2 diabetes (T2D), sustained remission of hyperglycemia can be induced by a single intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1), and the mediobasal hypothalamus (MBH) was recently implicated as the brain area responsible for this effect. To better understand the cellular response to FGF1 in the MBH, we sequenced >79,000 single-cell transcriptomes from the hypothalamus of diabetic Lep
Indexed as
Agouti-Related ProteinAnimalsAstrocytesBlood GlucoseCell CommunicationCell NucleusDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Dietary SucroseDiet, High-FatFibroblast Growth Factor 1HumansHypoglycemic AgentsHypothalamusInjections, IntraventricularLeptinAgouti-Related ProteinAgrp protein, mouseBlood GlucoseDietary SucroseFibroblast Growth Factor 1Hypoglycemic AgentsLeptinMC4R protein, mouseMelanocortinsMelanocyte-Stimulating HormonesReceptor, Melanocortin, Type 4Receptors, MelanocortinRecombinant ProteinsSHU 9119
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.